Partnering in Retinal Health

Our ambition is clear: to transform the retinal health landscape, developing targeted solutions that allow us to preserve the retina, protect people’s way of life and prevent vision loss. Collaborations with academic institutions, biotech partners and leaders in ophthalmic digital technology to co-create and pioneer advancements in retinal health will accelerate the development of tools to enable earlier detection of disease and disease progression, and the development of much-needed new treatments. We are actively pursuing new early-science collaborations in our areas of partnering interest and look forward to expanding our community of innovation partners in retinal health.

Our experience in retinal diseases

We have a strong foundation in research in diabetic retinopathies and are applying knowledge and insights from oncology, inflammation, neurodegeneration, fibrosis and cardiometabolic diseases. This means we have the ability to tackle the multifactorial pathophysiology of retinal diseases to address the serious medical need for earlier and more targeted treatment of retinal conditions.

Our retinal condition research focus

Our research takes a holistic approach, targeting key mechanisms in the pathogenesis of retinal conditions – vascular dysfunction, neuronal dysfunction and inflammation.  We are pursuing both oral and intravitreal treatments as part of an innovative pre-clinical and clinical portfolio grounded in these mechanisms.  The core areas we are researching include: 

Also: retinal vein occlusion, uveitis, retinopathy of prematurity.

Our partnering interests offer various opportunities for collaboration, with other companies and academic institutions, to complement our pipeline and advance treatment and delivery. Read our flyer to find out more about partnering with us.